Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) Director Thomas Hamilton purchased 70,000 shares of the stock in a transaction that occurred on Thursday, November 12th. The shares were acquired at an average cost of $2.67 per share, for a total transaction of $186,900.00. Following the completion of the transaction, the director owned 70,000 shares of the company’s stock, valued at $186,900. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Larimar Therapeutics Price Performance
Larimar Therapeutics stock traded up $0.32 during midday trading on Friday, hitting $3.02. The company’s stock had a trading volume of 2,531,459 shares, compared to its average volume of 1,257,255. The company has a market cap of $313.72 million, a price-to-earnings ratio of -1.55 and a beta of 0.73. Larimar Therapeutics, Inc. has a 1-year low of $1.91 and a 1-year high of $6.42. The company has a 50-day moving average price of $2.93 and a two-hundred day moving average price of $3.76.
Wall Street Analyst Weigh In
Several research analysts have recently commented on LRMR shares. Wedbush reaffirmed an “outperform” rating on shares of Larimar Therapeutics in a report on Tuesday. Wall Street Zen downgraded shares of Larimar Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Larimar Therapeutics in a research note on Thursday, October 15th. Finally, Leerink Partners began coverage on Larimar Therapeutics in a research report on Monday, September 14th. They set an “outperform” rating and a $13.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $10.33.
Get Our Latest Stock Analysis on LRMR
Key Larimar Therapeutics News
Here’s some of the latest news about LRMR:
- Positive Sentiment: CEO Carole Ben-Maimon, CFO Michael Celano, COO John B. Jr. Harlow, insider Gopi Shankar, and directors Frank Thomas and Joseph Truitt together purchased 52,810 shares for roughly $195,000. Director Thomas Hamilton separately bought 70,000 shares for $186,900. Insider purchase report Hamilton SEC filing
- Neutral Sentiment: The supplied coverage also notes H.C. Wainwright maintained a Buy rating; no rating change or fresh price-moving catalyst was reported. Analyst rating report
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the stock. Blue Owl Capital Holdings LP lifted its position in Larimar Therapeutics by 0.3% during the third quarter. Blue Owl Capital Holdings LP now owns 9,923,904 shares of the company’s stock worth $31,707,000 after purchasing an additional 32,147 shares during the period. BlackRock Inc. bought a new position in Larimar Therapeutics in the 2nd quarter valued at about $17,318,000. Marshall Wace LLP increased its holdings in Larimar Therapeutics by 9.1% in the 3rd quarter. Marshall Wace LLP now owns 2,195,954 shares of the company’s stock valued at $7,005,000 after buying an additional 183,496 shares during the period. AIGH Capital Management LLC bought a new position in Larimar Therapeutics in the 3rd quarter valued at about $5,911,000. Finally, Dimensional Fund Advisors LP raised its position in shares of Larimar Therapeutics by 143.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 798,462 shares of the company’s stock valued at $3,592,000 after buying an additional 470,968 shares in the last quarter. Institutional investors own 91.92% of the company’s stock.
Larimar Therapeutics Company Profile
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.
Recommended Stories
- Five stocks we like better than Larimar Therapeutics
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
